AMIKIN INJECTION Solution for injection Ref.[6157] Active ingredients: Amikacin

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2018  Publisher: Bristol-Myers Squibb Pharmaceuticals Limited, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH

Product name and form

AMIKIN INJECTION 100MG/2ML.

Pharmaceutical Form

Solution for administration to human beings by injection.

Qualitative and quantitative composition

Each vial contains in 2 mL amikacin sulfate equivalent to amikacin activity 100 mg (100,000 international units).

Excipient with known effect: Each vial contains 2.64 mg (0.13 mmol) sodium metabisulfite (E223).

For the full list of excipients, see section 6.1.

Active Ingredient
Description
Amikacin
List of Excipients

Sodium metabisulfite (E223)
Sodium citrate
Sulphuric acid
Water for injection

Pack sizes and marketing

Five 2 mL flint glass Type 1 vial with butyl rubber stopper and aluminium seal in a cardboard carton.

Marketing authorization holder

Bristol-Myers Squibb Pharmaceuticals Limited, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH

Marketing authorization dates and numbers

PL 11184/0136

Date of first authorisation: 26th August 1976
Date of latest renewal: 25th November 2005

Drugs

Drug
Countries
AMIKIN
Hong Kong, United Kingdom
 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈